Hutchmed Regulatory News (HCM)

18 Jul 2007 07:00

Hutchison China Meditech Limited18 July 2007 Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) Notice of Interim Results London, Wednesday, 18 July 2007: Chi-Med will be announcing its interim resultsfor the six months ended 30 June 2007 on Thursday, 9 August 2007. Ends Enquiries Chi-Med Telephone: +852 2121 8200Christian Hogg, CEO Citigate Dewe Rogerson Telephone: +44 (0) 20 7638 9571Anthony Carlisle Mobile: +44 (0) 7973 611 888Yvonne Alexander Mobile: +44 (0) 7866 610 682 About Chi-Med Chi-Med is the holding company of a pharmaceutical and healthcare group basedprimarily in China and was admitted to trading on the Alternative InvestmentMarket of the London Stock Exchange in May 2006. Chi-Med is focused onresearching, developing, manufacturing, and selling pharmaceuticals, healthsupplements and other consumer health and personal care products derived fromTraditional Chinese Medicine and botanical ingredients. Chi-Med is majority owned by Hutchison Whampoa Limited, an internationalcorporation listed on the Main Board of The Stock Exchange of Hong Kong Limited. This information is provided by RNS The company news service from the London Stock Exchange